Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

436
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
436
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

364
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
364
Analgesia and Pain Management01:25

Analgesia and Pain Management

793
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
793
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

1.8K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.8K
Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

Local Anesthetics: Clinical Application as Epidural Anesthesia

499
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
499
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

199
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
199

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Alcohol Use Disorder and Alcohol-related Liver Disease in Women Undergoing Cervical Cancer Screening: A Missed Opportunity to Screen?

Journal of addiction medicine·2026
Same author

CTA as preferred imaging modality for pulmonary embolism in pregnancy: an update on diagnostic imaging rates.

American journal of obstetrics & gynecology MFM·2026
Same author

Racial Disparities in Urine Toxicology Screening Among Pregnant People Admitted to Labor and Delivery.

Journal of addiction medicine·2025
Same author

Young Birthing Age and Postpartum Outcomes.

American journal of perinatology·2025
Same author

Correction: Obstetrics and Gynecology Provider Experience Screening for Harmful Alcohol Use: An Unmet Need for Standardized Screening and Intervention.

Cureus·2025
Same author

Obstetrics and Gynecology Provider Experience Screening for Harmful Alcohol Use: An Unmet Need for Standardized Screening and Intervention.

Cureus·2024

Related Experiment Video

Updated: Sep 12, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.4K

The Opioid Epidemic and Perinatal Health.

Suzanne O'Nan1, Elizabeth A Hoover1, Cresta Jones1

  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical School, 606 24th Avenue South, Suite 401, Minneapolis, MN 55455, USA.

Obstetrics and Gynecology Clinics of North America
|August 6, 2025
PubMed
Summary

Opioid use disorder (OUD) in pregnancy is a serious concern, but medications like methadone and buprenorphine improve outcomes. Harm reduction strategies are crucial for reducing overdose deaths.

Keywords:
BuprenorphineFentanylMethadoneNeonatal opioid withdrawal syndromeOpioid use disorderPregnancy

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

329
Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.1K

Related Experiment Videos

Last Updated: Sep 12, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.4K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

329
Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

3.1K

Area of Science:

  • Obstetrics and Gynecology
  • Addiction Medicine
  • Neonatal Health

Background:

  • Opioid misuse, opioid use disorder (OUD), and overdose pose significant risks to maternal and infant health, particularly during the perinatal and postpartum periods.
  • Existing medications for OUD, such as methadone and buprenorphine, are effective in reducing overdose risk and improving perinatal outcomes.
  • Ongoing research explores novel medications and formulations to expand treatment options for OUD in pregnant individuals.

Purpose of the Study:

  • To review the current landscape of OUD treatment in pregnancy.
  • To highlight the importance of medication-assisted treatment (MAT) for OUD.
  • To discuss necessary adaptations in obstetric and pediatric care and the role of harm reduction.

Main Methods:

  • Literature review of current OUD treatments in perinatal care.
  • Analysis of the impact of MAT on maternal and neonatal outcomes.
  • Examination of harm reduction strategies and their effectiveness.

Main Results:

  • Medications for OUD, including methadone and buprenorphine, significantly decrease the risk of pregnancy-associated overdose.
  • These medications are associated with improved perinatal outcomes.
  • Harm reduction tools like naloxone (Narcan) and sterile syringe programs are vital for preventing overdose mortality.

Conclusions:

  • OUD management during pregnancy requires a comprehensive approach integrating MAT and harm reduction.
  • Adjustments in obstetric and pediatric care are essential for optimizing maternal, fetal, and neonatal well-being.
  • Continued investigation into new OUD treatments is necessary to enhance care options.